These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease. Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099 [TBL] [Abstract][Full Text] [Related]
9. Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD. Hirai T; Lin PY; Simonetta F; Maas-Bauer K; Turkoz M; Mavers M; Baker J; Negrin RS Blood Adv; 2021 Jun; 5(11):2528-2538. PubMed ID: 34100904 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Wu Y; Schutt S; Paz K; Zhang M; Flynn RP; Bastian D; Sofi MH; Nguyen H; Dai M; Liu C; Chang YJ; Blazar BR; Yu XZ Blood; 2018 Apr; 131(17):1974-1986. PubMed ID: 29530952 [TBL] [Abstract][Full Text] [Related]
11. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Leveque-El Mouttie L; Koyama M; Le Texier L; Markey KA; Cheong M; Kuns RD; Lineburg KE; Teal BE; Alexander KA; Clouston AD; Blazar BR; Hill GR; MacDonald KP Blood; 2016 Aug; 128(6):794-804. PubMed ID: 27338097 [TBL] [Abstract][Full Text] [Related]
12. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease. Shao L; Lie AK; Zhang Y; Wong CH; Kwong YL Ann Hematol; 2015 Sep; 94(9):1493-504. PubMed ID: 25963280 [TBL] [Abstract][Full Text] [Related]
13. IL-Y Aggravates Murine Chronic Graft- Wan L; Jin Z; Hu B; Lv K; Lei L; Liu Y; Song Y; Zhu Y; Gong H; Xu M; Du Y; Xu Y; Liu H; Wu D; Liu Y Front Immunol; 2020; 11():559740. PubMed ID: 33329519 [TBL] [Abstract][Full Text] [Related]
14. Extrafollicular CD4 Deng R; Hurtz C; Song Q; Yue C; Xiao G; Yu H; Wu X; Muschen M; Forman S; Martin PJ; Zeng D Nat Commun; 2017 Oct; 8(1):978. PubMed ID: 29042531 [TBL] [Abstract][Full Text] [Related]
15. Host-residual invariant NK T cells attenuate graft-versus-host immunity. Haraguchi K; Takahashi T; Matsumoto A; Asai T; Kanda Y; Kurokawa M; Ogawa S; Oda H; Taniguchi M; Hirai H; Chiba S J Immunol; 2005 Jul; 175(2):1320-8. PubMed ID: 16002737 [TBL] [Abstract][Full Text] [Related]
17. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. Hotta M; Yoshimura H; Satake A; Tsubokura Y; Ito T; Nomura S Eur J Immunol; 2019 Jan; 49(1):179-191. PubMed ID: 30457669 [TBL] [Abstract][Full Text] [Related]
18. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302 [TBL] [Abstract][Full Text] [Related]
19. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163 [TBL] [Abstract][Full Text] [Related]